AI Summary
→ WHAT IT COVERS Three Labiotech journalists — Jules Adam, Willow Sharnival, and Rui Peter — each identify five biopharma companies to watch in 2026, spanning radiopharma, gene therapy, psychedelics, GLP-1 obesity drugs, and cardiovascular medicine, totaling 15 companies with near-term clinical catalysts. → KEY INSIGHTS - **Abivax maintenance data as inflection point:** Abivax's oral microRNA therapy for ulcerative colitis drove a roughly fivefold stock increase after positive phase three induction data in 2025. The critical 2026 catalyst is maintenance data confirming durability of remission. Separately, M&A speculation involving Eli Lilly adds a second layer of investor attention worth monitoring alongside the clinical readout. - **Radiopharma maturation signal:** Radiopharma is transitioning from niche to platform, evidenced by big pharma entering the space and growing attention to isotope supply chains and manufacturing logistics — historically overlooked infrastructure. ITM (Isotope Technologies Munich) serves as a sector barometer, combining its own pipeline with isotope supply capabilities and multi-cycle experience in the European market. - **GLP-1 competitive pressure on Novo Nordisk:** Novo Nordisk faces structural pressure in 2026 from a lapsed GLP-1 patent in Canada opening generic competition, Pfizer acquiring a GLP-1 asset Novo bid on, and internal pipeline diversification via next-generation candidate Amicretin. Tracking Novo reveals how dominant GLP-1 franchises respond when market exclusivity erodes and competition intensifies simultaneously. - **Psychedelic trial design as competitive differentiator:** MindMed's MM-120 holds FDA breakthrough therapy designation and is in phase three trials for generalized anxiety disorder and major depressive disorder, with top-line anxiety results expected in the first half of 2026. Rigorous trial design — specifically addressing functional blinding issues that derailed Lykos Therapeutics' MDMA PTSD application — positions MindMed ahead of sector peers. - **Chinese-licensed assets entering global trials:** Both Kilera Therapeutics and Braveheart Bio licensed cardiovascular and metabolic candidates from Jiangsu Hengrui Pharmaceuticals. Kilera's GLP-1/GIP dual agonist showed 22.8% mean weight loss at 36 weeks in phase two at higher doses, with a $600M series B funding a global phase three program launching in 2026 — a replicable pipeline-building model worth tracking. → NOTABLE MOMENT Kilera Therapeutics raised $400M at launch, then secured an additional $600M series B — totaling $1B — for a single GLP-1/GIP obesity asset licensed from a Chinese company. Investors committed this capital based largely on phase three data from Chinese trials, signaling a shift in how global biopharma evaluates non-Western clinical evidence. 💼 SPONSORS None detected 🏷️ Biopharma Pipeline, GLP-1 Obesity Drugs, Gene Therapy, Radiopharma, Psychedelic Medicine